Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback